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rate variability (HRV) by Holter electrocardiogram is a valid, non-invasive method to assess for autonomic modulation of sino-atrial discharge [2] . Attenuation in HRV has been demonstrated to be a potent marker of premature cardiac death in patients with high cardiovascular risk [3] . Briefly, reduction in HRV may be related, in part, to alterations in cardiovascular structure, changes in hemodynamics and/or derangements in its metabolic milieu (e.g. control of diabetes mellitus and/or uremia) [4, 5] . Given that daily hemodialysis (DHD) was demonstrated to reduce LVM and blood pressure while enhancing dialysis dose compared with conventional hemodialysis (HD) [6] , we hypothesized that DHD might augment or restore HRV compared with conventional HD.
The Frequent HD Network (FHN) Daily Trial aimed to examine the effects of frequent (6x per week) HD (in the form of in-center DHD) versus conventional thrice weekly HD on multiple intermediate outcome measures [6, 7] . Owing to limitations in sample size, the FHN Daily Trial was not designed to assess the effects of frequent HD on death or major health events. Nine prespecified domains were identified by the investigators, including one related to cardiac structure and function. Among the cardiac domain's secondary outcomes was the change in HRV.
The primary objective of the present report is to describe the effects of frequent HD on HRV and to explore which, if any, baseline patient characteristics appear to modify such an effect. We also explored potential mechanistic pathways that might influence the therapeutic response to frequent HD.
M AT E R I A L S A N D M E T H O D S
The FHN Daily Trial was a multicenter, randomized, prospective trial of in-center HD sponsored by the National Institute of Health, National Institutes Diabetes, Digestive and Kidney Diseases (NIDDK) and the Center for Medicare and Medical Services (CMS). The design, inclusion and exclusion criteria have been described previously [7] . Patients were enrolled between March 2006 and May 2009 and the trial concluded in May 2010. The trial protocol was approved by the local Institutional Review Board at each participating site. An independent Data Safety Monitoring Board provided oversight of the trial.
Dialysis intervention
Patients in the conventional arm remained on their usual three times per week HD prescription subject to a prescribed equilibrated K t /V urea of >1.1, a standardized K t /V urea of >2.0 and a treatment time of ≥2.5 h/session. Patients randomized to the frequent arm of the Daily Trial were targeted to an equilibrated K t /V n , where V n = 3.271 × V 2/3 , of 0.9 provided that the length of the session was between 1.5 and 2.75 h.
Heart rate variability All subjects randomized in the trial were asked to undergo 24-h Holter testing at baseline. However, the Holter measurements were not required for randomization, and the study population for this manuscript is restricted to 207 of 245 patients who actually provided measurements at baseline. Study staff measured continuous heart rate recordings using the KCI X5 digital Holter recorder (KCI Technology and Services, NJ). All study coordinators were trained and demonstrated competence in obtaining Holter tracings. Electrocardiographic data were couriered to and stored at the core laboratory in Toronto. We analyzed the acquired data centrally in a blinded manner as previously reported [8, 9] . Only normal sinus recordings were used to assess HRV. We determined low-frequency (LF) harmonic (0.05-0.15 Hz) (sympathetic modulation of heart rate) and high-frequency (HF) harmonic (0.15-0.5 Hz) ( parasympathetic modulation of heart rate) contributions to spectral power. LF/HF was used to denote sympathetic-to-parasympathetic ratio. We computed R-R intervals and their standard deviation (SDNN, a measure of beat-to-beat variability).
Cardiac magnetic resonance imaging (CMRI)
We measured LVM and biventricular volumes by cardiac magnetic resonance imaging (CMRI) in all randomized patients at baseline and at 12 months where feasible. All CMRI images were analyzed centrally in a blinded manner. CMRI was performed on 1.5-T magnetic resonance imaging systems (minimum gradient performance: peak strength ≥12 mT/m, slew rate ≥40 mTm/s) with dedicated surface coils. Sites were required to use standardized protocols utilizing breath-held, retrospective electrocardiogram-gated steadystate free precession imaging in contiguous short-axis views (8 mm slice thickness, 2 mm gap) that were carefully prescribed from localizer long-axis images. Imaging parameters were adjusted on each specific CMRI scanner to provide 20-25 cardiac phases with an in-plane spatial resolution superior of ≤2 mm and a temporal resolution of <50 ms. Using validated software (Argus, Siemens medical Solutions, Erlangen, Germany), we measured the myocardial volume on end-diastolic frames by manual tracing of endocardial and epicardial contours. We excluded papillary muscles from the calculation of myocardial mass. Subsequently, this volume was multiplied by the specific density of the myocardium (1.05 g/cm 3 ) to obtain LVM [10] . Similarly, we traced biventricular endocardial contours in end-diastole and end-systole to derive end-diastolic and end-systolic volumes. We used the formula of DuBois and DuBois to index LVM to body surface area [11] . We calculated the anthropometric volume using the Watson equation [12] . We defined LV dilation as end-diastolic volume (EDV)/body surface area >111.7 mL/m 2 (male) or >99.3 mL/m 2 (female) and LV hypertrophy as mass/body surface area >84.1 g/m 2 (male) or >66.8 g/m 2 (female) [13] . The treatment effect of frequent HD on myocardial mass was assessed by examining the differences in LVM. A reduction of >60 g in LVM was defined arbitrarily as a 'pronounced response.'
Physical performance
We used the Short Physical Performance Battery (SPPB) to capture the level of physical functioning. The SPPB [14] measures (i) the time needed (in seconds) to walk 4 m at a normal pace; (ii) the time needed to stand up and sit down five times as quickly as possible from a chair with the arms folded
across the chest; and (iii) a timed balance test that measures the ability to maintain balance with feet together in three positions (side by side, semi-tandem and tandem). Each of the three performance measures are assigned a score ranging from 0 to 4, with 0 being the inability to complete the test and 4 indicating the highest level of performance. The total SPPB score ranges from 0 to 12.
Body composition
Body composition was assessed by single-frequency (50 kHz; Quantum, RJL Systems, Clinton Township, MI) bioimpedance (BIA) at baseline and 12 months in the Daily Trial. The protocol instructed clinical centers to implement the BIA procedure before a mid-week HD session for subjects with at least one intact leg and arm when feasible; however, a minority of BIA assessments were performed on other days or after dialysis. We measured reactance (Xc) and resistance (R), and calculated phase angle, the arc tangent of the Xc-to-R ratio. We multiplied the arc tangent of Xc/R by 180/π to convert from radians to degrees. We used reactance to estimate total body potassium (TBK) by the method of Kotler et al. [15] . We estimated body cell mass (BCM) using the following equation:
Intracellular water was then calculated as 0.73 × BCM [16] . The summaries of the observed data are restricted to 131 subjects with nonmissing Holter measurements at baseline and Month 12. b The adjusted means and treatment effects were estimated under a mixed-effects analysis applied to the 207 subjects of the Daily Trial Holter Cohort. c The low-and high-frequency components and their sum were log transformed for estimation of adjusted means and treatment effects; these results are expressed as percentage changes in geometric means. The medians, 10th and 90th percentiles are expressed in ms 2 without log transformation.
O R I G I N A L A R T I C L E
We estimated adiposity (fat mass) by subtracting fat-free mass [estimated as total body water (TBW/0.73)] from total postdialysis body weight.
Subgroups
We a priori prespecified 12 subgroup factors to explore whether baseline demographic or clinical variables modified any effect of frequent HD on change in HRV. These baseline subgroup factors were: age (≤50 years or >50 years), urine volume ( < 100 mL or ≥100 mL), LV hypertrophy, LV dilatation (see CMRI methods), congestive heart failure (yes/no), extracellular water/total body water (ECW/TBW)(above and below median of 0.514), hemoglobin concentration (≤11.9 mg/dL or >11.9 mg/dL), interdialytic weight gain (above and below median of 2.93 kg), residual renal clearance (none or >0), use of beta blockers or calcium channel blockers and diabetes status (yes/no).
Intermediate outcomes considered in correlational analyses
We a priori defined seven intermediate measures reflecting possible hemodynamic or structural pathways leading to changes in HRV: ECW/TBW, heart rate, LVEDV, LVM, predialysis systolic blood pressure, the difference between the minimum intradialytic and pre-dialysis systolic blood pressures, and SPPB.
Data analysis
Descriptive statistics for continuous variables were summarized using mean ± SD or medians and 10th and 90th percentiles as appropriate. Categorical variables were summarized using frequencies and proportions. Descriptive summaries of changes in treatment-related variables are provided for the constant cohort with nonmissing values at baseline and 12 months after randomization. Due to positive skewness, the variables LF, HF and LF + HF were each log transformed prior to statistical analyses. For these outcomes, estimates of mean changes and treatment effects were expressed as percent differences in geometric means. The effects of randomized treatment assignment on HRV were estimated by applying a mixed-effects model to baseline and 12-month values using an unstructured covariance matrix with covariate adjustment including a time interaction for the baseline level of the outcome and clinical center. This analytic approach accounted for any 
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early HRV measurement in the analysis of changes to later time points in cases for patients who died or dropped out of the study during the follow-up period. We prespecified log LF, log HF and SDNN as the primary HRV outcomes. For each of the prespecified subgroup factors, we extended the basic mixed-effects model to relate the change in the primary HRV parameters to treatment assignment, the baseline factor and to appropriate interaction terms between the treatment assignment and the baseline factor. The primary assessment of treatment interactions with quantitative subgroup factors was based on a test for linear interaction, which treated the subgroup factor as a continuous variable; estimated treatment effects are also provided for the subgroups defined by prespecified cutoffs for descriptive purposes. We present Pvalues for the interactions without adjustment for multiple comparisons.
The primary analyses for this manuscript were restricted to 131 patients with both baseline and follow-up Holter measurements. In sensitivity analyses, the mean changes in Holter outcomes were compared between the randomized treatment groups after using multiple imputation to impute missing 12-month follow-up measurements. Missing responses for each of the Holter outcomes were multiply imputed five times using a Monte-Carlo Markov Chain algorithm assuming multivariate normality. The predictor variables in the imputation model were treatment assignment, the baseline and follow-up levels of LVM, LVEDV, the ratio of ECW/TBW estimated from BIA, pre-dialysis systolic blood pressure, pre-dialysis serum albumin, heart rate and the SF-36 Physical Health Composite. Statistical inferences for the multiply imputed data were performed using the standard adjustments to standard errors of Rubin [17] .
We depicted the association of changes in the three primary HRV parameters, log LF, log HF and SDNN, with changes in average ECW, heart rate, LVEDV, LVM, pre-dialysis systolic blood pressure and SPPB for individual patients using scatter plots with separate nonparametric local regression curves for each treatment group, and also provided Pearson's correlations between the changes for each group. The end of study levels of average pre-dialysis systolic blood pressure was averaged over measurements at Months 10, 11 and 12. We performed all analyses using SAS version 9.2. We considered two-tailed P-values <0.05 as statistically significant.
R E S U LT S
Selected baseline demographics, clinical characteristics, cardiovascular risk profile, medication use and biochemical status are summarized in Table 1 for the 207 subjects with baseline Holter measurements. In general, the Holter study participants' demographics were similar to the overall randomized subjects. Following randomization, 7 and 6 of the Holter cohort died and were transplanted, respectively, in the frequent HD group, while 7 and 11 died or were transplanted in the conventional HD group. An additional 23 frequent HD and 22 conventional dialysis patients in the Holter cohort had missing follow-up Holter assessments, leaving a total of 131 subjects with both baseline and follow-up measurements (73 frequent HD subjects and 58 conventional HD subjects).
Baseline to Month 12 change in LF was augmented by 50% (95% CI 6.1, 112%; P = 0.022) and LF + HF was augmented by 40% (3.3%, 88.4%, P = 0.03) in patients assigned to daily HD compared with conventional HD. Changes in HF and SDNN were similar between the daily and conventional HD groups. (Table 2 ) Intermediate outcomes are summarized in Table 3 . The sensitivity analyses performed using multiple imputation for subjects with missing 12-month measurements showed similar trends in all outcome variables.
Among the complete cohort of subjects randomized in the Daily Trial (n = 245), nine experienced a reduction in LVM of ≥60 g; all nine were randomized to frequent HD. All were younger than 50 years of age and had baseline LVM exceeding 140 g. One of the nine had diabetes. Eight had negligible residual urine volume. Eight of these patients had HRV measurements. Descriptively, among the pronounced responders, changes in HF and SDNN appeared equally impressive (Table 4) .
Among the 12 prespecified subgroup factors, the effects of DHD on LF were attenuated in older patients and patients with diabetes. (Figure 1) .
In correlational analyses, 12-month changes in HF and SDNN were modestly associated with changes in LVM (partial r = −0.17, P = 0.053; partial r = −0.20, P = 0.03, respectively) and LVEDV (partial r = −0.18, P = 0.04; partial r = −0.18, P = 0.05, respectively), after adjusting for the randomized treatment assignment. Similar changes in log LF were not associated with changes in any of the seven candidate measures. (Figures 2 and 3) .
D I S C U S S I O N
DHD does not appear to normalize the sympatho/vagal balance in ESRD; however, there is a global increase in HRV, which suggests closer approximation of normal physiology. In addition, our observations suggest that modification of LVM may be linked with changes in vagal modulation of heart rate.
Studies of HRV and ESRD have consistently shown a decrement in HRV [2, 18, 19] . Indeed, in patients with advanced heart failure or ESRD, heart rate becomes invariant F I G U R E 1 . Shown are estimated percent differences in geometric mean changes between the frequent and conventional HD groups, with 95% CIs. The P-values refer to tests of interactions of the treatment with age (as a continuous variable) and diabetic status. The P-values were not adjusted for multiple testing.
implicating sustained cardiac adrenergic activation and loss of parasympathetic modulation of heart rate [20] . Reduced HRV has been established as an independent risk factor in patients with a high cardiac risk profile [21] , exemplified by the Autonomic Tone and Reflexes After Myocardial Infarction [3] trial, a study that enrolled 1284 patients with a recent (<28 days) myocardial infarction. Sympathetic overactivity was assessed by SDNN. During 21 months of follow-up, patients with SDNN <70 ms experienced a 3.2-fold increase in cardiac mortality. Similar observations have been noted in ESRD. Oikawa et al. found that SDNN <75 ms was associated with a 3.6-fold increase in cardiovascular death among 383 patients on chronic HD [22] . Nishimura et al. [23] found that 5-year survival was 98.1% in patients with LF/HF (sympatho/vagal balance) <1.9; sudden cardiac death-free survival was only 29% in patients with LF/HF >1. 9 .
The present results demonstrated that DHD augmented HRV globally. In particular, LF was elevated in the daily HD arm by 49% compared with conventional HD. Limited observational evidence does support our findings. Zilch et al. [24] F I G U R E 2 . Shown are scatter plots relating change from baseline to 12 months in left ventricular mass and in left ventricular EDV to the change in the log transformed high-frequency component within the two treatment groups. Local regression curves are displayed.
O R I G I N A L A R T I C L E
studied 11 patients before and 6 months after conversion from conventional to daily HD. The mean arterial pressure decreased from 113 ± 11 to 98 ± 9 mmHg. Muscle sympathetic nerve activity (a measure of sympathetic discharge to skeletal muscle) decreased from 39 ± 19 to 28 ± 15 bursts/min. In the general population, secondary prevention trials with patients with coronary artery disease who received medications (betablockers, calcium channel blockers, angiotensin-converting enzyme inhibitors), behavioral treatment or exercise training have consistently shown global increases in HRV [25] . The mechanism underlying the effect of DHD on autonomic modulation of heart rate was not the primary objective of the present investigation; however, it is tempting to speculate that changes in cardiac structure and hemodynamics may account, at least in part, for the present results.
Left ventricular hypertrophy in ESRD is associated with sympathetic activation and vagal withdrawal [26, 27] . Norepinephrine is known to cause cardiomyocyte hypertrophy in F I G U R E 3 . Shown are scatter plots relating change from baseline to 12 months in left ventricular mass and in left ventricular EDV to the change in the SD of RR intervals within the two treatment groups. Local regression curves are displayed.
vitro [28] . Zoccali et al. examined the association between plasma norepinephrine and LVH in patients with ESRD. These investigators demonstrated that 91 of 197 (46%) patients had plasma norepinephrine concentrations above the upper limit of the normal range. In addition, patients with the highest tertile of plasma norepinephrine concentrations were 3.8-fold more likely to have concentric LVH [29] . Similarly, in a cohort of 154 HD patients with diabetes, Nishimura et al. [30] showed a modest inverse association between left ventricular mass index and HF harmonic (r 2 = 0.08). DHD has been demonstrated to reduce LVM and LVEDV [31] . In heart failure, dilatation of cardiac chambers may contribute to the reduction of HRV. Horner et al. [32] demonstrated the importance of mechano-electric feedback by using animal heart models with a specially built device designed to stretch the sinoatrial node. Stretch of the sinoatrial node decreased SDNN and the HF component of HRV. Given the demonstrated association between changes in HF and SDNN with changes in LVM and LVEDV, our present results support the concept that restoration of LVM and cardiac chamber size may be accompanied by improvement in HRV.
Repetitive myocardial ischemia has been demonstrated to induce a state of increased sympathetic tone [33] . DHD was shown to reduce sessional volume removal and ultrafiltration rate [6] , which had been linked with intradialytic myocardial ischemia [34] . Jefferies et al. showed that daily versus conventional HD was associated with reduced myocardial stunning [35] . Given that DHD may reduce recurrent myocardial ischemia, it is also plausible that improvement in the myocardial supply-to-demand ratio may in turn reduce central sympathetic outflow.
This study has several important strengths. First, results were derived from a randomized clinical trial, mitigating some bias and confounding inherent in observational studies. Second, we objectively assessed multiple, valid metrics of HRV. Third, we studied a relatively large and generalizable sample. Although participation in a clinical trial nearly always indicates selection bias of some degree, by the usual metrics (i.e. demographics, comorbidity, etc.) trial subjects were reasonably representative of the North American HD population, and participants in the Holter substudy were similar to the larger trial cohort. This study also has several important limitations. Holter measurements were not required for randomization and because the measurements were only collected once more at the end of the trial, we were unable to assess HRV changes among subjects who failed to complete the 12-month intervention. In total, we obtained both the baseline and followup measurements for 63% of those patients who had baseline Holter recordings. The power to detect smaller, but clinically significant differences in HF or SDNN was low and, perhaps more importantly, we were unable to determine whether the HRV-induced changes in HRV that we did detect led to a reduction in sudden death or other major cardiovascular events.
In summary, relative to conventional HD, daily HD augments HRV, principally by altering the LF component. Reduction of LVM by DHD was associated with increased vagal modulation of heart rate (HF) and with increased beatto-beat heart rate variation (SDNN), suggesting an important functional correlate to the structural effects of DHD on the heart in uremia.
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